Navigation Links
PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
Date:11/8/2012

INCLINE VILLAGE, Nev., Nov. 8, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012, at 4:30 p.m. ET in New York City.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)  

This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the event to allow for any software download that may be necessary. The archived webcast will be available for seven days following the presentation.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.  


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
2. John A. Orwin Joins Array BioPharma Board Of Directors
3. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
5. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
6. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
7. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
8. PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
9. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
11. PDL BioPharma Announces Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... ... June 19, 2017 , ... As Vice ... EDETEK’s products including training, implementation, support, and client process and SOP development. , ... has previously held leadership roles for service providers and top-tier pharmaceuticals, and as ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cambridge ... announced that its Anzo Smart Data Lake® (Anzo SDL) solution was named ... the 2017 Software & Information Industry Association (SIIA) CODiE Awards. , Finalists ...
(Date:6/15/2017)... ... June 15, 2017 , ... angelMD announced the closure of ... Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this ... of Saranas’ recently announced $4 million Series B financing round. , Saranas is ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... materials for pumps and process equipment, has appointed Andrew Ondish as Territory Sales ... Ondish holds a B.S. degree in Petroleum Engineering from Colorado School of Mines. ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):